Literature DB >> 2198793

Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncológico Cooperativo del Sur.

J E Perez1, M Machiavelli, B A Leone, A Romero, M G Rabinovich, C T Vallejo, A Bianco, R Rodriguez, M A Cuevas, L A Alvarez.   

Abstract

The medical records of 510 patients with metastatic breast cancer were retrospectively reviewed. Seventy-seven patients with metastases confined to skeleton and 73 patients bearing visceral-only disease were identified. All patients had a disease-free interval greater than or equal to 6 months and received systemic therapy with any of the following modalities: chemotherapy, hormonotherapy, or chemohormonotherapy. The clinical features, response to treatment, and survival were analyzed and compared for both groups. Median survival of patients with osseous metastases was 28 months, while it was 13 months for those patients with a visceral pattern (p less than 0.001). Response rates to first and second line systemic therapy for both metastatic patterns showed no significant differences, suggesting a similar degree of sensitivity or resistance in both groups. Objective regression to first therapy was 45% in the group with bony disease and 41% among patients with visceral involvement; median duration of response was 16 months and 13 months, respectively. In both groups progressive disease conserved the original metastatic pattern in most patients. We conclude that although a superiority in survival was evident for the osseous metastatic pattern, for these patients efforts should be made to select the least aggressive therapy in order to avoid excessive toxicity. Further studies are needed to confirm our findings.

Entities:  

Mesh:

Year:  1990        PMID: 2198793     DOI: 10.1097/00000421-199008000-00005

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  16 in total

1.  Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.

Authors:  Naoki Niikura; Jun Liu; Naoki Hayashi; Shana L Palla; Yutaka Tokuda; Gabriel N Hortobagyi; Naoto T Ueno; Richard L Theriault
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

2.  Hepatic metastases from breast cancer.

Authors:  Arianna Rubino; Roberto Doci; Jean Claude Foteuh; Emanuela Morenghi; Susanna Fissi; Casimiro Giorgetta; Islam Abumalouh; Luca Di Tommaso; Leandro Gennari
Journal:  Updates Surg       Date:  2010-12

3.  The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study.

Authors:  José Pablo Leone; Bernardo Amadeo Leone; Ariel O Zwenger; Carlos Teodoro Vallejo; Alberto Omar Romero; Mario Raúl Machiavelli; Juan Eduardo Pérez; Julieta Leone
Journal:  Breast Cancer Res Treat       Date:  2021-01-03       Impact factor: 4.872

4.  External validation of the number of risk factors score in a palliative care outpatient clinic at a comprehensive cancer center.

Authors:  Paul Glare; Imran Shariff; Howard T Thaler
Journal:  J Palliat Med       Date:  2014-05-28       Impact factor: 2.947

5.  A multidisciplinary bone metastases clinic at Toronto Sunnybrook Regional Cancer Centre - A review of the experience from 1999 to 2005.

Authors:  Kathy K Li; Emily Sinclair; Joan Pope; Macey Farhadian; Kristin Harris; Julie Napolskikh; Albert Yee; Lawrence Librach; Lesia Wynnychuk; Cyril Danjoux; Edward Chow; On Behalf Of The Bone; Metastases Team
Journal:  J Pain Res       Date:  2008-09-01       Impact factor: 3.133

6.  Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis.

Authors:  Naoki Niikura; Jun Liu; Naoki Hayashi; Shana L Palla; Yutaka Tokuda; Gabriel N Hortobagyi; Naoto T Ueno; Richard L Theriault
Journal:  Oncologist       Date:  2011-01-25

7.  Does liver resection provide long-term survival benefits for breast cancer patients with liver metastasis? A single hospital experience.

Authors:  Jee Ye Kim; Joon Seong Park; Seung Ah Lee; Jae Keun Kim; Joon Jeong; Dong Sup Yoon; Hy-De Lee
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

8.  Advanced breast cancer and its prevention by screening.

Authors:  H J de Koning; B M van Ineveld; J C de Haes; G J van Oortmarssen; J G Klijn; P J van der Maas
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

9.  Cost of managing women presenting with stage IV breast cancer in the United Kingdom.

Authors:  E Remák; L Brazil
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

10.  The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile.

Authors:  Jean Berthelet; Verena C Wimmer; Holly J Whitfield; Antonin Serrano; Thomas Boudier; Stefano Mangiola; Michal Merdas; Farrah El-Saafin; David Baloyan; Jordan Wilcox; Steven Wilcox; Adam C Parslow; Anthony T Papenfuss; Belinda Yeo; Matthias Ernst; Bhupinder Pal; Robin L Anderson; Melissa J Davis; Kelly L Rogers; Frédéric Hollande; Delphine Merino
Journal:  Sci Adv       Date:  2021-07-07       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.